Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Am. J. Ophthalmol., Jun;143(6):958-969 (2007)
Erythropoiesis-stimulating agents in oncology.
J Natl Compr Canc Netw., Jul;6(6):565-75 (2008)
Erythropoietin in cancer patients.
Annu. Rev. Med., 60:181-92 (2009)
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Clin. Cancer Res., Jan;15(1):390-9 (2009)
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
Cancer., Mar;115(5):1121-31 (2009)
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Clin. Cancer Res., Oct;15(19):6267-76 (2009)
Do we need a different set of response assessment criteria for tumor immunotherapy?
Clin. Cancer Res., Dec;15(23):7116-8 (2009)
Randomized controlled trials of the erythroid-stimulating agents in cancer patients.
Cancer Treat. Res., 157:195-215 (2011)
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Clin. Cancer Res., Jun;17(12):4101-9 (2011)
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Cancer., Mar;97(5):1312-20 (2003)
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Clin. Cancer Res., Mar;9(3):998-1008 (2003)
Current developments in cancer vaccines and cellular immunotherapy.
J. Clin. Oncol., Jun;21(12):2415-32 (2003)
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
J. Immunol., Apr;172(8):4762-9 (2004)
Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
Control Clin Trials., Aug;25(4):400-7 (2004)
Entering a new era in the management of tumor-associated involution.
J Support Oncol., 3(1):51-2 (2005)
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Cancer Gene Ther., Jun;12(6):516-27 (2005)
The development of erythropoietic agents in oncology.
Expert Opin Emerg Drugs., Aug;10(3):553-67 (2005)
Novel interactions of vitamin E and estrogen in breast cancer.
Nutr Cancer., 52(1):43-8 (2005)
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
Cancer Immunol. Immunother., Jun;55(6):663-71 (2006)
Cancer patient survival and erythropoietin.
J Natl Compr Canc Netw., Nov;3(6):796-804 (2005)
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
J. Immunol., Apr;176(8):4757-65 (2006)
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.
Clin. Cancer Res., Aug;12(15):4662-70 (2006)
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
J. Immunol., Apr;166(8):5300-8 (2001)
Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.
Mol. Immunol., Nov;37(16):943-50 (2000)
alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.
Cancer Res., Dec;61(24):8782-6 (2001)
CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Cancer Res., Dec;61(24):8787-93 (2001)
Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery.
Exp. Hematol., Apr;30(4):374-80 (2002)
Therapeutic options in the management of renal cell carcinoma.
Semin. Oncol., Jun;29(3 Suppl 7):41-6 (2002)
Cancer immunotherapy using gene-modified dendritic cells.
Curr Gene Ther., Feb;2(1):57-78 (2002)
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.
Leukemia., Aug;16(8):1484-9 (2002)
Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
Cancer Gene Ther., Nov;9(11):875-83 (2002)
Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer.
Nutr Cancer., 42(2):180-5 (2002)
Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion.
Proc. Natl. Acad. Sci. U.S.A., Feb;100(4):1751-6 (2003)
Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.
Blood., Oct;90(8):2939-51 (1997)
In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2.
Hum. Gene Ther., Dec;8(18):2173-82 (1997)
Impact of epoetin alfa in chemotherapy-associated anemia.
Semin. Oncol., Oct;25(5):571-6 (1998)
Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
J. Immunol., Nov;161(10):5607-13 (1998)
Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities.
Anticancer Res., 19(2A):1165-70 (1999)
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Cancer Res., Jul;59(13):3134-42 (1999)
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
Cancer Res., Jul;59(13):3064-7 (1999)
p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
Cancer Res., Sep;59(17):4369-74 (1999)
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.
Cancer Gene Ther., 6(6):523-36 (1999)
Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
Cancer Res., Apr;60(8):2218-24 (2000)
Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects.
J. Natl. Cancer Inst., May;92(9):750-3 (2000)
Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Cancer Res., Nov;60(22):6457-64 (2000)
Recombinant beta-serine-interferon in hairy cell leukemia compared prospectively with results with recombinant alpha-interferon.
Cancer., Jul;64(2):409-13 (1989)
Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection.
Blood., Jun;75(11):2137-42 (1990)
Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor.
Am. J. Dis. Child., Jul;145(7):808-12 (1991)
Cost considerations in therapy with myeloid growth factors.
Am J Hosp Pharm., Jul;50(7 Suppl 3):S19-26 (1993)
Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.
Cancer Res., Jul;57(14):2865-9 (1997)
Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer.
Urology., Aug;58(2):283-8 (2001)
Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Cancer., Jul;72(1):82-90 (1993)
Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
Cytometry., Jun;22(2):103-10 (1995)
Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer.
J. Natl. Cancer Inst., Aug;89(15):1123-31 (1997)
Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
J. Nucl. Med., Mar;39(3):431-5 (1998)
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.
J. Leukoc. Biol., Sep;64(3):358-67 (1998)
Hyperammonemia following allogeneic bone marrow transplantation.
Am. J. Hematol., Oct;38(2):140-1 (1991)
Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies.
Semin. Oncol., Aug;19(4):386-94 (1992)
Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET.
J Comput Assist Tomogr., 16(5):684-9 (1992)
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Eur. J. Cancer., 29A Suppl 7:S23-30 (1993)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
J Transl Med., 6:22 (2008)
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia., Aug;12(8):637-49 (2010)
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.
J Transl Med., 8:89 (2010)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
J. Clin. Oncol., Dec;23(35):8968-77 (2005)
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer.
Blood., Oct;96(7):2385-90 (2000)
Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy.
Bone Marrow Transplant., May;23 Suppl 2:S21-7 (1999)
Whole body skeletal imaging with [18F]fluoride ion and PET.
J Comput Assist Tomogr., 17(1):34-41 (1993)
Hematologic supportive care of the critically ill cancer patient.
Semin. Oncol., Jun;27(3):375-83 (2000)
Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.
J. Immunother., Jan;23(1):59-66 (2000)
Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
J. Immunother., Apr;11(3):198-208 (1992)
Hemostatic abnormalities in multiple myeloma and related disorders.
Hematol. Oncol. Clin. North Am., Dec;6(6):1301-14 (1992)
Use of positron emission tomography in oncology.
Oncology (Williston Park, N.Y.)., Jul;7(7):41-6, 49-50; discussion 50-2, 55 (1993)
Basic principles of positron emission tomography in oncology: quantitation and whole body techniques.
Wien. Klin. Wochenschr., 106(15):496-504 (1994)
Economic outcomes associated with the use of hematopoietic growth factors.
Oncology (Williston Park, N.Y.)., Nov;9(11 Suppl):93-105 (1995)
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
J. Clin. Oncol., Aug;16(8):2659-71 (1998)
The colony-stimulating factors: biology and clinical use.
Oncology (Williston Park, N.Y.)., Sep;4(9):25-32; discussion 32-4 (1990)
Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
Blood., May;77(10):2109-17 (1991)
Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor.
Ann. Intern. Med., Nov;109(10):789-95 (1988)
Evolving therapy of hairy cell leukemia.
Cancer., Feb;59(3 Suppl):652-7 (1987)